Tigecylcine warning from the FDA
Thursday, September 2nd, 2010The IV antibiotic tigecycline received a label change and warning from the FDA, given the drug has been associated with higher mortality than similar broad spectrum antibiotics. Although a mechanism for the higher mortality has not been elucidated, the FDA is recommending the use of alternative antibiotics, rather than tigecycline, in hospitalized patients wtih serious infections (FDA site)